Powered by

Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells; -- Collaboration to Leverage oNKo-innate's Deep Expertise in NK Cell Tumor Biology to Discover Novel Therapies in Immuno-

Apr 21, 2020 - Business Wire
Partnership Announcement

Gilead Sciences, Inc. (Nasdaq: GILD), Kite, a Gilead Company, and oNKo-innate announced the companies have entered into a three-year cancer immunotherapy research collaboration to support discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200421005271/en/

Current cancer immunotherapy approaches primarily focus ...